{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:31:38Z","timestamp":1795195898265,"version":"4.10.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Res"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1038\/s41422-019-0224-x","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T04:20:46Z","timestamp":1567484446000},"page":"846-861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":263,"title":["Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade"],"prefix":"10.1038","volume":"29","author":[{"given":"Nicolas","family":"Jacquelot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5788-6840","authenticated-orcid":false,"given":"Maria P.","family":"Roberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9067-8557","authenticated-orcid":false,"given":"Connie P. M.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-8641","authenticated-orcid":false,"given":"Miles C.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Verlingue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"Ferrere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Becharef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"V\u00e9tizou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Daill\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Messaoudene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Enot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Marigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Foong Ngiow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-5905","authenticated-orcid":false,"given":"Armelle","family":"Prevost-Blondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Olivier","family":"Gaudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vancheswaran","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paule","family":"Opolon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-7240","authenticated-orcid":false,"given":"Mark J.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bronte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-7576","authenticated-orcid":false,"given":"Jennifer","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"224_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"224_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","volume":"13","author":"MJ Smyth","year":"2016","unstructured":"Smyth, M. J., Ngiow, S. F., Ribas, A. & Teng, M. W. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143\u2013158 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"224_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri1936","volume":"6","author":"L Zitvogel","year":"2006","unstructured":"Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715\u2013727 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"224_CR4","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"224_CR5","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/ng.3677","volume":"48","author":"N Riaz","year":"2016","unstructured":"Riaz, N. et al. Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nat. Genet. 48, 1327\u20131329 (2016).","journal-title":"Nat. Genet."},{"key":"224_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"224_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"224_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"224_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).","journal-title":"Cell"},{"key":"224_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"224_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269\u2013281 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"224_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"key":"224_CR13","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem, P. T. et al. PD-1 Blockade with pembrolizumab in advanced merkel-cell carcinoma. N. Engl. J. Med. 374, 2542\u20132552 (2016).","journal-title":"N. Engl. J. Med."},{"key":"224_CR14","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517\u20132526 (2011).","journal-title":"N. Engl. J. Med."},{"key":"224_CR15","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"224_CR16","doi-asserted-by":"crossref","unstructured":"Hirsch, L., Zitvogel, L., Eggermont, A. & Marabelle, A. PD-Loma: a cancer entity with a shared sensitivity to the PD-1\/PD-L1 pathway blockade. Br J Cancer. 120, 3\u20135 (2019).","DOI":"10.1038\/s41416-018-0294-4"},{"key":"224_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon, K. M., Johnson, C. E. & Williams, C. J. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 62, 29\u201339 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"224_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","volume":"42","author":"D Pardoll","year":"2015","unstructured":"Pardoll, D. Cancer and the immune system: basic concepts and targets for intervention. Semin. Oncol. 42, 523\u2013538 (2015).","journal-title":"Semin. Oncol."},{"key":"224_CR19","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"224_CR20","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"224_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231\u2013235 (2015).","journal-title":"Nature"},{"key":"224_CR22","doi-asserted-by":"publisher","first-page":"eaan3311","DOI":"10.1126\/scitranslmed.aan3311","volume":"10","author":"NJ Neubert","year":"2018","unstructured":"Neubert, N. J. et al. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci. Transl. Med. 10, eaan3311 (2018).","journal-title":"Sci. Transl. Med."},{"key":"224_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-ctla-4 therapy. Cell 167, 397\u2013404 e399 (2016).","journal-title":"Cell"},{"key":"224_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama, S. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 10501 (2016).","journal-title":"Nat. Commun."},{"key":"224_CR25","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315, 1600\u20131609 (2016).","journal-title":"JAMA"},{"key":"224_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to pd-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"224_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).","journal-title":"Nat. Commun."},{"key":"224_CR28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","volume":"3","author":"HT Khong","year":"2002","unstructured":"Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation of \u201ctumor escape\u201d phenotypes. Nat. Immunol. 3, 999\u20131005 (2002).","journal-title":"Nat. Immunol."},{"key":"224_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jnci\/88.2.100","volume":"88","author":"NP Restifo","year":"1996","unstructured":"Restifo, N. P. et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88, 100\u2013108 (1996).","journal-title":"J. Natl. Cancer Inst."},{"key":"224_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"224_CR31","doi-asserted-by":"publisher","first-page":"127ra137","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube, J. M. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra137 (2012).","journal-title":"Sci. Transl. Med."},{"key":"224_CR32","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg, J. et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490, 412\u2013416 (2012).","journal-title":"Nature"},{"key":"224_CR33","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1158\/0008-5472.CAN-15-1082","volume":"75","author":"SF Ngiow","year":"2015","unstructured":"Ngiow, S. F. et al. A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to Anti-PD1. Cancer Res. 75, 3800\u20133811 (2015).","journal-title":"Cancer Res."},{"key":"224_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cytogfr.2015.01.001","volume":"26","author":"TF Gajewski","year":"2015","unstructured":"Gajewski, T. F. & Corrales, L. New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 26, 175\u2013178 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"224_CR35","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","volume":"76","author":"ME Rodriguez-Ruiz","year":"2016","unstructured":"Rodriguez-Ruiz, M. E. et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mabs and are dependent on cd8 t cells and crosspriming. Cancer Res. 76, 5994\u20136005 (2016).","journal-title":"Cancer Res."},{"key":"224_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","volume":"90","author":"MJ Smyth","year":"2006","unstructured":"Smyth, M. J., Dunn, G. P. & Schreiber, R. D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90, 1\u201350 (2006).","journal-title":"Adv. Immunol."},{"key":"224_CR37","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","volume":"77","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Suppression of type i ifn signaling in tumors mediates resistance to anti-pd-1 treatment that can be overcome by radiotherapy. Cancer Res. 77, 839\u2013850 (2017).","journal-title":"Cancer Res."},{"key":"224_CR38","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301\u20131309 (2014).","journal-title":"Nat. Med."},{"key":"224_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ni1213","volume":"6","author":"GP Dunn","year":"2005","unstructured":"Dunn, G. P. et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6, 722\u2013729 (2005).","journal-title":"Nat. Immunol."},{"key":"224_CR40","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4049\/jimmunol.170.1.270","volume":"170","author":"V Bronte","year":"2003","unstructured":"Bronte, V. et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170, 270\u2013278 (2003).","journal-title":"J. Immunol."},{"key":"224_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fcimb.2014.00050","volume":"4","author":"O Dussurget","year":"2014","unstructured":"Dussurget, O., Bierne, H. & Cossart, P. The bacterial pathogen Listeria monocytogenes and the interferon family: type I, type II and type III interferons. Front. Cell. Infect. Microbiol. 4, 50 (2014).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"224_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.coph.2017.05.002","volume":"35","author":"G Mondanelli","year":"2017","unstructured":"Mondanelli, G., Ugel, S., Grohmann, U. & Bronte, V. The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. Curr. Opin. Pharm. 35, 30\u201339 (2017).","journal-title":"Curr. Opin. Pharm."},{"key":"224_CR43","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","volume":"64","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez, P. C. et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839\u20135849 (2004).","journal-title":"Cancer Res."},{"key":"224_CR44","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","volume":"222","author":"PC Rodriguez","year":"2008","unstructured":"Rodriguez, P. C. & Ochoa, A. C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222, 180\u2013191 (2008).","journal-title":"Immunol. Rev."},{"key":"224_CR45","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/eji.1830250436","volume":"25","author":"M Modolell","year":"1995","unstructured":"Modolell, M., Corraliza, I. M., Link, F., Soler, G. & Eichmann, K. Reciprocal regulation of the nitric oxide synthase\/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25, 1101\u20131104 (1995).","journal-title":"Eur. J. Immunol."},{"key":"224_CR46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.canlet.2010.12.013","volume":"302","author":"H Verbeke","year":"2011","unstructured":"Verbeke, H. et al. Isotypic neutralizing antibodies against mouse GCP-2\/CXCL6 inhibit melanoma growth and metastasis. Cancer Lett. 302, 54\u201362 (2011).","journal-title":"Cancer Lett."},{"key":"224_CR47","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540\u20131554 e1512 (2016).","journal-title":"Cell"},{"key":"224_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"224_CR49","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","volume":"162","author":"W Hugo","year":"2015","unstructured":"Hugo, W. et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162, 1271\u20131285 (2015).","journal-title":"Cell"},{"key":"224_CR50","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.redox.2015.08.009","volume":"6","author":"F Vannini","year":"2015","unstructured":"Vannini, F., Kashfi, K. & Nath, N. The dual role of iNOS in cancer. Redox Biol. 6, 334\u2013343 (2015).","journal-title":"Redox Biol."},{"key":"224_CR51","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.2174\/0929867323666160812145641","volume":"23","author":"AW Girotti","year":"2016","unstructured":"Girotti, A. W., Fahey, J. M. & Korytowski, W. Multiple means by which nitric oxide can antagonize photodynamic therapy. Curr. Med. Chem. 23, 2754\u20132769 (2016).","journal-title":"Curr. Med. Chem."},{"key":"224_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7676","volume":"6","author":"G Lu","year":"2015","unstructured":"Lu, G. et al. Myeloid cell-derived inducible nitric oxide synthase suppresses M1 macrophage polarization. Nat. Commun. 6, 6676 (2015).","journal-title":"Nat. Commun."},{"key":"224_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.immuni.2010.07.001","volume":"33","author":"M Farlik","year":"2010","unstructured":"Farlik, M. et al. Nonconventional initiation complex assembly by STAT and NF-kappaB transcription factors regulates nitric oxide synthase expression. Immunity 33, 25\u201334 (2010).","journal-title":"Immunity"},{"key":"224_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1074-7613(00)80460-4","volume":"8","author":"A Diefenbach","year":"1998","unstructured":"Diefenbach, A. et al. Type 1 interferon (IFNalpha\/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 8, 77\u201387 (1998).","journal-title":"Immunity"},{"key":"224_CR55","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/1521-4141(2000)30:8<2257::AID-IMMU2257>3.0.CO;2-U","volume":"30","author":"J Mattner","year":"2000","unstructured":"Mattner, J. et al. Regulation of type 2 nitric oxide synthase by type 1 interferons in macrophages infected with Leishmania major. Eur. J. Immunol. 30, 2257\u20132267 (2000).","journal-title":"Eur. J. Immunol."},{"key":"224_CR56","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.4049\/jimmunol.1600584","volume":"197","author":"L Moreira-Teixeira","year":"2016","unstructured":"Moreira-Teixeira, L. et al. Type I IFN inhibits alternative macrophage activation during mycobacterium tuberculosis infection and leads to enhanced protection in the absence of IFN-gamma signaling. J. Immunol. 197, 4714\u20134726 (2016).","journal-title":"J. Immunol."},{"key":"224_CR57","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.4049\/jimmunol.175.3.1586","volume":"175","author":"T Yamazaki","year":"2005","unstructured":"Yamazaki, T. et al. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J. Immunol. 175, 1586\u20131592 (2005).","journal-title":"J. Immunol."},{"key":"224_CR58","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2016.08.004","volume":"30","author":"I Marigo","year":"2016","unstructured":"Marigo, I. et al. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell 30, 377\u2013390 (2016).","journal-title":"Cancer Cell"},{"key":"224_CR59","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nmeth.2030","volume":"9","author":"T Gaj","year":"2012","unstructured":"Gaj, T., Guo, J., Kato, Y., Sirk, S. J. & Barbas, C. F. 3rd Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Methods 9, 805\u2013807 (2012).","journal-title":"Nat. Methods"},{"key":"224_CR60","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"224_CR61","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jid.2015.12.042","volume":"136","author":"N Jacquelot","year":"2016","unstructured":"Jacquelot, N. et al. Immunophenotyping of stage III melanoma reveals parameters associated with patient prognosis. J. Invest. Dermatol. 136, 994\u20131001 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"224_CR62","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827\u2013837 (2016).","journal-title":"Cancer Discov."},{"key":"224_CR63","unstructured":"Wang, H., Zhai, T. & Wang, C. NanoStringDiff: differential expression analysis of NanoString nCounter data. R package version 1.12.0 (2018)."},{"key":"224_CR64","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/bioinformatics\/bts188","volume":"28","author":"D Waggott","year":"2012","unstructured":"Waggott, D. et al. NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics 28, 1546\u20131548 (2012).","journal-title":"Bioinformatics"},{"key":"224_CR65","doi-asserted-by":"publisher","first-page":"e1462431","DOI":"10.1080\/2162402X.2018.1462431","volume":"7","author":"DP Enot","year":"2018","unstructured":"Enot, D. P., Vacchelli, E., Jacquelot, N., Zitvogel, L. & Kroemer, G. TumGrowth: an open-access web tool for the statistical analysis of tumor growth curves. Oncoimmunology 7, e1462431 (2018).","journal-title":"Oncoimmunology"}],"container-title":["Cell Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41422-019-0224-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41422-019-0224-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41422-019-0224-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:18:23Z","timestamp":1684603103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41422-019-0224-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["224"],"URL":"https:\/\/doi.org\/10.1038\/s41422-019-0224-x","relation":{},"ISSN":["1001-0602","1748-7838"],"issn-type":[{"value":"1001-0602","type":"print"},{"value":"1748-7838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]},"assertion":[{"value":"5 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.K. reports grants and personal fees from Bayer Healthcare, grants from Genentech, grants from Glaxo Smyth Kline, grants and personal fees from Lytix Pharma, grants from PharmaMar, grants from Sotio, grants from Vasculox, other from Bristol Myers Squibb Foundation France, other from everImmune, other from Samsara Therapeutics, outside the submitted work. L.Z. has the following financial relationships to disclose, none of which deals with the submitted work: Scientific advisory boards at Lytix Pharma, EpiVax, NeoVax and Tusk Pharma; Administrative board: Transgene; Grant\/Research support from Glaxo Smith Kline, Merus, Tusk Roche and Incyte; Founder and shareholder: everImmune. M.C.A. reports honorarium, travel support and advisory board participation from Merck, unrelated to the current work. J.W. and V.G. are inventors on a US patent application (PCT\/US17\/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome, unrelated to this work submitted. J.W. reports compensation for speaker\u2019s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, MedImmune and Bristol-Myers Squibb; consultant\/advisory board membership for AstraZeneca, Merck, Biothera Pharmaceuticals and Microbiome DX; consultant\/advisory board membership and research support from GlaxoSmithKline, Roche\/Genentech, Bristol-Myers Squibb, and Novartis. V.G. reports consultancy fees from MicrobiomeDX and ExpertConnect, and honoraria from ExcelCME and Kansas Society of Clinical Oncology. M.J.S. has scientific research agreements with Bristol Myers Squibb and Tizona Therapeutics and is an advisory board member for Compass Therapeutics and Tizona Therapeutics. A.M.E. declares receipt over the last 2 years of Honoraria for Scientific Advisory Boards and Data Monitoring Safety Board from the following companies: BMS, GSK, Incyte, IO Biotech, ISA-Pharmaeuticals, MedImmune, Merck-Serono, MSD, Novartis, Pfizer, Sanofi, Sellas, SkylineDx. P.A.A. has\/had a consulting or advisory role for BMS, Roche-Genentech, MSD, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, Newlink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs. Sandoz, Immunocore. He also received research funds from BMS, Roche-Genentech, Array, and travel support from MSD. V.B. reports advisory board participation from ITeos Therapeutics Sa, Tusk Therapeutics Ltd, Io Biotech ApS, Xios Therapeutics, Codiak BioSciences. Over the last 5 years, J.-C.S. has received consultancy fees from AstraZeneca, Astex, Clovis, GSK, GamaMabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche\/Genentech, Sanofi, Servier, Symphogen, and Takeda. He has been a full-time employee of MedImmune since September 2017. He is a shareholder of AstraZeneca and Gritstone. L.V. reports personal fees from Adaptherapy, personal fees from Pierre-Fabre, grants from Bristol-Myers Squibb, outside the submitted work. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}